生物仿制药法案》通过十年后，美国生物制剂系统知识产权信息匮乏。

IF 15.8 1区医学 Q1 Medicine

PLoS Medicine Pub Date : 2024-04-25 DOI:10.1371/journal.pmed.1004381

Robin Feldman

引用次数: 0

摘要

在这篇《政策论坛》文章中，罗宾-费尔德曼（Robin Feldman）讨论了现行立法是如何造成美国生物药专利信息不足的。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Paucity of intellectual property rights information in the US biologics system a decade after passage of the Biosimilars Act.

In this Policy Forum piece, Robin Feldman discusses how current legislation contributes to informational deficits around drug patents for biologic drugs in the United States.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

PLoS Medicine MEDICINE, GENERAL & INTERNAL-

CiteScore

17.60

自引率

0.60%

发文量

227

审稿时长

4-8 weeks

期刊介绍： PLOS Medicine is a prominent platform for discussing and researching global health challenges. The journal covers a wide range of topics, including biomedical, environmental, social, and political factors affecting health. It prioritizes articles that contribute to clinical practice, health policy, or a better understanding of pathophysiology, ultimately aiming to improve health outcomes across different settings. The journal is unwavering in its commitment to uphold the highest ethical standards in medical publishing. This includes actively managing and disclosing any conflicts of interest related to reporting, reviewing, and publishing. PLOS Medicine promotes transparency in the entire review and publication process. The journal also encourages data sharing and encourages the reuse of published work. Additionally, authors retain copyright for their work, and the publication is made accessible through Open Access with no restrictions on availability and dissemination. PLOS Medicine takes measures to avoid conflicts of interest associated with advertising drugs and medical devices or engaging in the exclusive sale of reprints.